Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.

doi:10.1016/j.eururo.2024.05.014

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.

European urology - 1 Oct 2024

Nordentoft Iver, Lindskrog Sia Viborg, Birkenkamp-Demtröder Karin, Gonzalez Santiago, Kuzman Maja, Levatic Jurica, Glavas Dunja, Ptashkin Ryan, Smadbeck James, Afterman Danielle, Lauterman Tomer, Cohen Yarin, Donenhirsh Zohar, Tavassoly Iman, Alon Ury, Frydendahl Amanda, Rasmussen Mads Heilskov, Andersen Claus Lindbjerg, Lamy Philippe, Knudsen Michael, Polak Paz, Zviran Asaf, Oklander Boris, Agerbæk Mads, Jensen Jørgen Bjerggaard, Dyrskjøt Lars

Abstract excerpt

BACKGROUND AND OBJECTIVE: Circulating tumor DNA (ctDNA) can be used for sensitive detection of minimal residual disease (MRD). However, the probability of detecting ctDNA in settings of low tumor burden is limited by the number of mutations analyzed and the plasma volume available. We used a whole-genome sequencing (WGS) approach for ctDNA detection in patients with urothelial carcinoma. METHODS: We used a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Transitional Cell

Share to Circulating Tumor DNA

Share to DNA Mutational Analysis

Share to Mutation

Share to Neoplasm, Residual

Share to Urinary Bladder Neoplasms

Share to Whole Genome Sequencing

Source

Open in PubMed

Identifiers

PMID: 38811314
DOI: 10.1016/j.eururo.2024.05.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.PMID 38811314Read ↗

Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinomaSemantic proximity Read ↗

High Sensitivity ctDNA Analysis Using a Novel Panel and NOIR-SS Technology for Monitoring Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling–informed personalized monitoring assaySemantic proximity Read ↗

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-upSemantic proximity Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-upSemantic proximity Read ↗

Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.Semantic proximity Read ↗

Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.Semantic proximity Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Clinical Utility of Serial Circulating Tumor DNA Analysis as a Minimally Invasive Biomarker in Advanced Urothelial Cancer.Semantic proximity Read ↗

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read ↗

Circulating Tumor DNA in Genitourinary Malignancies: Current Applications and Future PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.